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ABSTRACT 
New Analytical method was developed for the estimation of Emtricitabine and Tenofovir Alafenamide Fumarate in drug product by liquid 
chromatography. The chromatographic separation was achieved on Cosmosil C18 column (250mm×4.6ID, 5µm) at ambient temperatur e. The 
separation achieved employing a mobile phase consists of   Methanol:water(80:20v/v). The flow rate was 0.8ml/ minute and ultra violet 
detector at 252nm. The average retention time for Emtricitabine and Tenofovir Alafenamide Fumarate found to be 4.277min and 5.293min. The 
proposed method was validated for selectivity, precision, linearity and accuracy. All validation parameters were within the acceptable range. 
The assay methods were found to be linear from 10-50µg/ml for Emtricitabine and 15-75µg/ml for Tenofovir Alafenamide Fumarate.   
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INTRODUCTION 
Drug Profile  
Emtricitabine: Emtricitabine (2'-deoxy-5-
fluoro3'thiacytidine, FTC), with trade name Emtriva is a 
nucleoside reverse transcriptase inhibitor (NRTI) for the 
prevention and treatment of HIV infection in adult 
 
Structure of emtricitabine 
  IUPAC Name: 4-amino-5-fluoro-1-[(2R, 5S)-
2(hydroxymethyl)-1, 3-oxathiolan-5-yl]-1,    
2dihydropyrimidin-2-one  
 Molecular formula: C8H10FN3O3S 
 Molecular Weight: 247.248 g/mol. 
 Solubility: Soluble in ACN, Water, and Methanol. 
 Pka: 14.29.    
Mechanism of action: Emtricitabine works by inhibiting 
reverse transcriptase, the enzyme that copies HIV RNA into 
new viral DNA. Emtricitabine is a synthetic nucleoside 
analogue of cytidine. It is phosphorylated by cellular 
enzymes to form emtricitabine 5'-triphosphate, which is 
responsible for the inhibition of HIV-1 reverse transcriptase. 
It competes with the natural substrate deoxycytidine 
5'triphosphate and incorporates into nascent viral DNA, 
resulting in early chain termination. Therefore emtricitabine 
inhibits the activity of HIV-1 reverse transcriptase (RT) both 
by competing with the natural substrate deoxycytidine 5'-
triphosphate and by its incorporation into viral DNA. By 
inhibiting HIV-1 reverse transcriptase, emtricitabine can 
help to lower the amount of HIV, or "viral load", in a patient's 
body and can indirectly increase the number of immune 
system cells (called T cells or CD4+ T-cells). Both of these 
changes are associated with healthier immune systems and 
decreased likelihood of serious  
Tenofovir Alafenamide Fumarate:  Tenofovir alafenamide 
fumarate (INN/USAN; trade name Vemlidy) is a nucleotide 
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reverse transcriptase inhibitor and a prodrug of tenofovir. It 
was developed by Gilead Sciences for use in the treatment of 
HIV infection and chronic hepatitis B, and is applied in the 
form of Tenofovir alafenamide fumarate (TAF). Closely 
related to the commonly used reverse transcriptase 
inhibitor Tenofovir disoproxil fumarate (TDF), TAF has 
greater antiviral activity and better distribution into 
lymphoid tissues than that agent. 
 
Structure of Tenofovir alafenamide fumarate 
IUPAC Name: Isopropyl (2S)-2-[[[(1R)-2-(6aminopurin-9-
yl)-1-methyl-ethoxy] methyl-phenoxyphosphoryl] amino] 
propanoate. 
Molecular formula: C21H29N6O5P. 
Molecular Weight: 476.466 g/mol. 
Solubility: Soluble in methanol, Acetonitrile and water 
Pka: 11.36 
Mechanism of action: Tenofovir alafenamide fumarate  is a 
nucleotide reverse transcriptase inhibitor (NRTI) and a 
novel ester prodrug of the antiretroviral tenofovir. Following 
oral administration, TAF is converted in vivo to tenofovir, an 
acyclic nucleoside phosphonate (nucleotide) analog of 
adenosine 5′-monophosphate. Tenofovir mimics normal 
DNA building blocks but is lacking a 3'-OH molecule required 
for phosphodiester bond linkage. By competing with regular 
nucleotides for incorporation into proviral DNA and 
prevention of the formation of the 5' to 3' phosphodiester 
linkage required for DNA elongation, Tenofovir causes early 
chain termination and prevents proviral DNA transcription. 
EXPERIMENTAL 
Equipments: The chromatographic technique performed on 
a HPLC workstation software, Cosmosil C18 
(250mm×4.6ID,5µ), Wenser ultra sonicator, Wenser high 
precision balance , Vaccum micro filtration unit with 0.45µ 
membrane filter was used in the study.   
Materials: Pharmaceutically pure sample of 
Emtricitabine/Tenofovir Alafenamide fumarate were 
obtained as gift samples from Mecleod pharmaceutical, 
Gujarat, India.   HPLC-grade Methanol and water    
Chromatographic conditions: 
Column: C18 column (250 x 4.6 mm,5µ)                                                                                         
Mobile phase: Methanol: Distill water in proportion of 80:20 
v/v                                                           
Detector: 252nm                                                                                                                              
Injection volume: 20 μl                                                                                                                     
Flow rate: 0.8 ml/min                                                                                                               
Temperature: Ambient                                                                                                                   
Run time: 10 min                                                                                                                                  
Diluents: Mobile Phase  
 
 
 
Selection of Mobile Phase  
Standard solution of EMT and TA were injected into the 
HPLC system and run in different solvent systems. Mixture 
of different solvents were tried in order to determine 
optimum chromatographic conditions for effective 
separation of EMT and TA. After several permutation and 
combination, it was found that mixture of methanol: water 
gives satisfactory results as compared to other mobile 
phases. Finally, the optimal composition of the mobile phase 
methanol: water in the ratio of 80:20v/v was selected, as it 
gave high resolution of EMT and TA with minimal tailing.  
Preparation of mobile phase: Mobile phase was prepared 
by mixing 80ml of methanol with 20ml of distilled water.   
Preparation of standard stock solution:About 45 mg of TA 
and 30 mg of EMT were accurately weighed & transferred to 
10 ml volumetric flasks. Both the drugs were dissolved in 5 
ml of mobile phase with shaking and then volume was made 
up to the mark with the mobile phase to get 4500µg/ml of 
TA and 3000µg/ml of EMT of standard stock solution of each 
drug. Then it was ultrasonicated for 10 minutes and filtered 
through 0.20µ membrane filter..   
Preparation of sample solution: Accurately weighed 
twenty tablets were ground to obtain fine powder 
equivalent to 200mg of Emtricitabine and 25 mg of 
Tenofovir Alafenamide fumarate sample were weighed and 
transferred to 100 ml of volumetric flask and dissolved in 
diluent. The flask was shaken and volume was made up to 
mark with diluents to give a primary stock solution. From 
the above solution 1 ml of solution is pipetted out into a 10 
ml volumetric flask and volume was made up to mark with 
diluents to give a solution containing 30µg/ml of 
Emtricitabine and 45µg/ml Tenofovir Alafenamide fumarate.   
RESULTS AND DISCUSSIONS 
Determination Of Working Wavelength (λ max): 10 mg of 
the Emtricitabine and Tenofovir Alafenamide fumarate 
standard drug is taken in a 10 ml volumetric flask and 
dissolved in Diluent and volume made up to the mark, from 
this solution 0.1ml is pipette into 10 ml volumetric flask and 
made upto the mark with the Water to give a concentration  
10 µg/ml. The above prepared solution is scanned in uv 
between 200-400 nm using Water as blank. The λmax was 
found to be 252nm. 
 
Figure: 1 Chromatogram of Emtricitabine and Tenofovir 
Alafenamide fumarate
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Method Validation  
Linearity: Linearity was studied by analyzing five standard 
solutions covering the range of 10-50g/mL for Emtricitabine 
and 15-75µg/ml of Tenofovir Alafenamide fumarate. From 
the primary stock solution 1.0ml, 1.5ml, 2.0ml, 2.5ml, 3.0ml  
and 1.5ml,3.0ml,45ml,60ml,75ml,of aliquots are pipetted 
into 10 ml volumetric flasks and made up to the mark with 
the mobile phase to give a concentrations of 10µg/mL, 
20µg/ml, 30µg/mL, 40µg/mL, 50µg/mL of Emtricitabine and 
15g/mL, 30µg/mL, 45µg/mL, 60µg/mL and 75µg/mL of 
Tenofovir Alafenamide fumarate.   
Calibration curve with concentration verses peak areas was 
plotted by injecting the above prepared solutions and the 
obtained data were subjected to regression analysis using 
the least squares method. 
 
 
Figure 2: Linearity (calibration) curve Emtricitabine 
 
Figure 3: Linearity (calibration) curve of Tenofovir 
alafenamide fumarate
Result: A linear relationship between peak areas versus 
concentrations was observed for Emtricitabine and 
Tenofovir Alafenamide fumarate in the range of 10% to 50% 
and 15% to75% of nominal concentration. Correlation 
coefficient was 0.9993 and 0.9991 for both Emtricitabine 
and Tenofovir  Alafenamide fumarate which prove that the 
method is linear in the range of 10% to 50% and 15% 
to75%. 
Limit of detection and limit of quantification: The limit of 
detection (LOD) and limit of quantification (LOQ) were 
separately determined based on standard deviation of the y-
intercept and the slope of the calibration curve by using the 
equations (1) and (2), respectively.                                                                                                                       
LOD = 3.3 σ /S ………. (1)                                                                                                  
LOQ =10 σ /S ……….. (2)  
Where, σ = the standard deviation of the response (STEYX) S 
= the slope of the calibration curve. Slope S may be 
estimated from the calibration curve of the analyte. 
  
Table 1: LOD and LOQ values Calculated from calibration curve                              . 
 Emtricitabine(mg) Tenofovir alafenamide fumarate 
LOD  0.079% 0.047% 
LOQ 0.24% 0.14% 
  
Precision  
Repeatability: The precision of the method was checked by 
repeated preparation (n=6) of 30µg/ml of Emtricitabine and 
45µg/ml of Tenofovir Alafenamide fumarate without 
changing the parameter of the proposed chromatographic 
method. And measure the peak areas and retention times. 
 
Table 2: Result of repeatability (intra-day) 
Drug Conc (µg/ml) Morning Evening  Mean %RSD 
  2532980 2533416   
Emtricitabine      30 2531529 2535640 2533059 0.06% 
  2532579 2532208   
  2870144 2871352   
   TAF       45 2867512 2874794 2871167 0.09% 
  2869554 2873645   
  
Intermediate precision: The Intra and Inter-day precision 
was determined by analysis of the marketed formulation on 
the same day at different time intervals and on different 
days respectively
 
Table 3: Result of repeatability (intra-day) 
Drug Conc (µg/ml) Day1 Day2  Mean %RSD 
  2532980 2529331   
Emtricitabine      30 2531529 2534937 2533059 0.06% 
  2532579 2535014   
  2870144 2872721   
   TAF       45 2867512 2872706 2871167 0.09% 
  2869554 2871935   
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Result:  The relative standard deviation values for 
repeatability precision were found less than 2%. %RSD of 
repeatability was 0.06% for Emtricitabine and 0.09% for 
tenofovir alafeamide fumarate and %RSD of intermediate 
precision was 0.08% for Emtricitabine and 0.07% for 
Tenofovir alafenamide fumarate. 
 
4.3 Accuracy 
The accuracy of the method was determined by calculating 
the recoveries of Emtricitabine and Tenofovir Alafenamide 
fumarate by analyzing solutions containing approximately 
50%, 100% and 150% of the working strength of 
Emtricitabine and Tenofovir Alafenamide fumarate. The 
percentage recovery results obtained are listed in Table 4 &5 
 
Table 4: The accuracy results for Emtricitabine 
%Concentration       Area Amount added 
(mg) 
Amount found 
(mg) 
% Recovery  Mean % 
recovery 
50% 2528334 10 29.94 99.8       
100% 3405037 20 39.93 99.82 99.80 
150% 4301062 30 49.90 99.8  
 
Table 5: The accuracy results for Tenofovir alafenamide fumarate 
%Concentration     Area Amount 
added(mg) 
Amount found 
(mg) 
% Recovery Mean % 
recovery 
50% 2869077 15 44.98 99.95  
100% 3944458 30 59.98 99.96 99.94 
150% 5067816 45 74.95 99.93  
 
 
Result: The accuracy study was performed for % recovery of 
Emtricitabine and Tenofovir alafenamide fumarate. The % 
recovery was found to be 99.80% and 99.94% respectively 
(NLT 98% and NMT 102%) 
Robustness: Robustness is the measure of a method remain 
unaffected by small, deliberate changes in method 
parameters like flow rate and detection wavelength on assay 
of the analyte of interest. Here the detection wavelength 
varied ±2nm and flow rate was varied ±0.2 ml/min. The 
results were shown in (Table no. 6&7). 
 
 
Table 6: Results of Emtricitabine 
Parameter     Area Mean SD %RSD 
 0.9 1572158    
Flowrate 0.7 1574736 1573945 1550.66 0.0985204 
 0.8 1574940    
 250 1575147    
Wavelenght 254 1574301 1574796 441 0.028003 
 252 1574940    
 
 
Table 7: Results of of Tenofovir alafenamide fumarate 
Parameter     Area Mean SD %RSD 
 0.9 1719803    
Flowrate 0.7 1722294 1720171 1964.57 0.1142178 
 0.8 1718417    
 250 1721703    
Wavelenght 254 1717724 1719281 2125.66 0.123636 
 252 1718417    
 
Result  
The results of Robustness of the present method had shown that changes are not significant we can say that the method is  
Robust. 
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Table 8: Summary for results of validation parameters 
Validation Parameter Acceptance criteria 
Results 
Emtricitabine 
Tenofovir alafenamide 
fumarate 
Linearity 
Correlation coefficient 
NLT  0.9990 
0.9991 0.9992 
Accuracy 
(%Recovery ) 
98 – 102 % 99.80 %  99.94% 
Precision 
Repeatability %RSD NMT 2.0 0.06 % 0.09 % 
Intermediate %RSD NMT 2.0 0.08 % 0.07 % 
 
Robustness 
Change in wavelength %RSD NMT 2.0 0.028 % 0.12 % 
Change in flow rate %RSD NMT 2.0 0.09% 0.11 % 
Limit of detection (µg/ml)  0.079 % 0.047 % 
Limit of  quantitation (µg/ml)  0.24% 0.14% 
 
CONCLUSION  
From the above experimental results it was concluded that, 
this newly developed method for the simultaneous 
estimation of Emtricitabine and Tenofovir Alafenamide 
fumarate was found to be simple, precise, accurate and high 
resolution and shorter retention time makes this method 
more acceptable and cost effective and it can be effectively 
applied for routine analysis in research institutions, quality 
control department in meant in industries, approved testing 
laboratories.  
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